Alzinova får FDA:s snabbspår för sitt alzheimervaccin

Biofarmabolaget Alzinovas vaccinkandidat mot Alzheimers sjukdom har beviljar Fast Track-status av USA:s läkemedelsmyndighet FDA.

Alzinova tar steg mot fas II-studie i USA

Biofarmabolaget Alzinova hoppas kunna inleda en fas II-studie med sin vaccinkandidat mot Alzheimers under andra halvåret 2025.

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

Ännu en alzheimerkandidat får snabbspår

USA:s läkemedelsmyndighet FDA har beviljat så kallad Fast Track Designation för ännu en läkemedelskandidat för behandling av tidig Alzheimers sjukdom.

Discover ZEISS ZEN core – now for electron microscopy

Watch the recording of our free webinar.

CSL miljardsatsar på ny behandling inom blodkoagulation

Australiensiska CSL har förvärvat en exklusiv option att köpa nederländska Varmx och dess läkemedelskandidat inom blodkoagulation. Affären kan potentiellt uppgå...

New Insights into Microscopy

Watch the recording of our free webinar.

New version of ISO 10993-1: the core standard for the biological evaluation of medical devices

ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...

Trumps order: Kräver lägre läkemedelspriser

USA:s hälsominister väntas inom 30 dagar sätta tydliga mål för lägre läkemedelspriser, med fokus på viktminskningsläkemedel. Det uppgav Vita huset under måndagen.

BMS and venture capital giant form new company

The American pharmaceutical company Bristol Myers Squibb, together with the venture capital firm Bain Capital, is forming a new biotech company. The company wil...

Explore the possibilities of the new ZEISS METROTOM 800 320 kV

Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.

Tau-targeted Alzheimer's drug gets Fast Track designation in the USA

Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

Wegovy approved in the U.S. for treatment of liver disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Novo Nordisk’s drug Wegovy to treat the serious liver condition known as MASH. ...

In-Depth Insights into the Most Useful ZEISS Metrology Expert Tips

Free webinar June 24th, 2025, 9:00-9:45 AM and 5:00-5:45 PM.

The FDA’s new transparency policy (Part 2)

In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory strategies to navigate the potential impact o...

Smartzoom 100 – The New Digital Microscope for Maximum Efficiency

Free webinar July 1, 9:00-9:45 AM CEST and 5:00-5:45 PM CEST.

Who pays for Rebecca Doe – and all of us?

Anna Törner on how easily we get used to the idea that healthcare is free - when it really is about how and who pays for it

First preterm infants study – a vital step for Neola

After years of developing an advanced lung monitoring system, Neola Medical has received some delightful news: permission to start its first clinical study on p...

Cantargia får snabbspår för antikroppen nadunolimab

Lundabaserade biotechbolaget Cantargia har beviljats Fast Track-status i USA för snabbare utveckling och granskning av sin läkemedelskandidat avsedd för behandl...

Lund University’s record-breaking recruitment – attracting researchers from around the world

The Swedish university is launching its largest international recruitment effort ever, aiming to hire 25 researchers globally, including several in the medical field.

Pharma Outsourcing – Find the Right Partner (2025)

Tau-inriktat alzheimerpreparat får snabbspår i USA

Amerikanska Biogens alzheimerkandidat BIIB080 har beviljats ”Fast Track” – ett snabbspår – av den amerikanska läkemedelsmyndigheten FDA.

How to Assure Quality within R&D Medical Devices

Free webinar on June 3rd, 2025, 9:00 - 9:45 AM CEST and 5:00 - 5:45 PM CEST.

Strategic Clarity: The New Currency in Life Science

In an industry shaped by rapid regulatory changes and global competition, leading life science companies are rethinking what it takes to succeed. Increasingly, ...